Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic's Q1 Sales Sag 20 Percent as R&D Grows and Loss Widens

NEW YORK (GenomeWeb News) — Transgenomic yesterday said first-quarter revenues decreased 20 percent as R&D spending rose 75 percent and its net loss ballooned by 276 percent.
Total receipts for the three months ended March 31 fell to $5.2 million from $6.5 million year over year.
However, CEO Craig Tuttle said revenue from Transgenomic’s reference labs grew 277 percent to $290,000. He said the company saw “continuous quarter over quarter growth in our reference laboratory business and improvement in our pharma contract pipeline.”
R&D spending rose to $1.1 million from $604,000 million year over year.
Transgenomic said its net loss rose to $1.2 million from $318,000 in the year-ago period.
Tuttle said he expects “cost-savings measures” to have an increasing impact over the second half of 2007.
Transgenomic said it had around $7.9 million in cash and cash equivalents as of March 31.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.